XBiotech Q2 FY26 net loss widens to $6.73 million; no revenue - XBIT News | RalliesXBiotech Q2 FY26 net loss widens to $6.73 million; no revenue
X
XBIT• Q2 FY26 results
- XBiotech posted a GAAP net loss of USD 6.73 million for the quarter ended June 30, 2026, widening from USD 1.76 million.
- Loss per share widened to USD 0.22 from USD 0.06.
- Operating loss widened to USD 6.15 million from USD 6.34 million.
- Research and development expense edged down 1% to USD 5.3 million; general and administrative expense fell 15% to USD 850,000.
- Cash and cash equivalents totaled USD 109.53 million at June 30, 2026, down from USD 125.55 million at Dec. 31, 2025.
PTBS
•
